10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Th1‐type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II‐dependent hypertension and vascular dysfunction

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Purpose

          Emerging evidence indicates that hypertension is mediated by immune mechanisms. We hypothesized that exposure to Porphyromonas gingivalis antigens, commonly encountered in periodontal disease, can enhance immune activation in hypertension and exacerbate the elevation in BP, vascular inflammation and vascular dysfunction.

          Experimental Approach

          Th1 immune responses were elicited through immunizations using P. gingivalis lysate antigens (10 μg) conjugated with aluminium oxide (50 μg) and IL‐12 (1 μg). The hypertension and vascular endothelial dysfunction evoked by subpressor doses of angiotensin II (0.25 mg·kg −1·day −1) were studied, and vascular inflammation was quantified by flow cytometry and real‐time PCR.

          Key Results

          Systemic T‐cell activation, a characteristic of hypertension, was exacerbated by Pgingivalis antigen stimulation. This translated into increased aortic vascular inflammation with enhanced leukocyte, in particular, T‐cell and macrophage infiltration. The expression of the Th1 cytokines, IFN‐γ and TNF‐α, and the transcription factor, TBX21, was increased in aortas of Pgingivalis/IL‐12/aluminium oxide‐immunized mice, while IL‐4 and TGF‐β were unchanged. These immune changes in mice with induced T‐helper‐type 1 immune responses were associated with an enhanced elevation of BP and endothelial dysfunction compared with control mice in response to 2 week infusion of a subpressor dose of angiotensin II.

          Conclusions and Implications

          These results support the concept that Th1 immune responses induced by bacterial antigens such as Pgingivalis can increase sensitivity to subpressor pro‐hypertensive insults such as low‐dose angiotensin II, thus providing a mechanistic link between chronic infection, such as periodontitis, and hypertension.

          Linked Articles

          This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          Inflammation, immunity, and hypertension.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension.

            The pathogenic role of T cells in hypertension has been documented well in recent animal studies. However, the existence of T-cell-driven inflammation in human hypertension has not been confirmed. Therefore, we undertook immunologic characterization of T cells from patients with hypertension and measured circulating levels of C-X-C chemokine receptor type 3 chemokines, which are well-known tissue-homing chemokines for T cells. We analyzed immunologic markers on T cells from patients with hypertension by multicolor flow cytometry. We then measured circulating levels of the C-X-C chemokine receptor type 3 chemokines, monokine induced by γ interferon (IFN), IFN γ-induced protein 10, and IFN-inducible T-cell α chemoattractant, in patients with hypertension and in age- and sex-matched control subjects by the cytometric bead array method. In addition, we examined histological features of IFN-inducible T-cell α chemoattractant expression from renal biopsy specimens of patients with hypertensive nephrosclerosis and control subjects. The total T-cell population from patients with hypertension showed an increased fraction of immunosenescent, proinflammatory, cytotoxic CD8(+) T cells. Circulating levels of C-X-C chemokine receptor type 3 chemokines were significantly higher in patients with hypertension than in control subjects. Furthermore, immunohistochemical staining revealed increased expression of the T-cell chemokine, IFN-inducible T-cell α chemoattractant, in the proximal and distal tubules of patients with hypertensive nephrosclerosis. Immunosenescent CD8(+) T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension, suggesting a role for T-cell-driven inflammation in hypertension. A more detailed characterization of CD8(+) T cells may offer new opportunities for the prevention and treatment of human hypertension.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Host defense against oral microbiota by bone-damaging T cells

              The immune system evolved to efficiently eradicate invading bacteria and terminate inflammation through balancing inflammatory and regulatory T-cell responses. In autoimmune arthritis, pathogenic TH17 cells induce bone destruction and autoimmune inflammation. However, whether a beneficial function of T-cell-induced bone damage exists is unclear. Here, we show that bone-damaging T cells have a critical function in the eradication of bacteria in a mouse model of periodontitis, which is the most common infectious disease. Bacterial invasion leads to the generation of specialized TH17 cells that protect against bacteria by evoking mucosal immune responses as well as inducing bone damage, the latter of which also inhibits infection by removing the tooth. Thus, bone-damaging T cells, which may have developed to stop local infection by inducing tooth loss, function as a double-edged sword by protecting against pathogens while also inducing skeletal tissue degradation.
                Bookmark

                Author and article information

                Contributors
                marta.czesnikiewicz-guzik@glasgow.ac.uk
                Journal
                Br J Pharmacol
                Br. J. Pharmacol
                10.1111/(ISSN)1476-5381
                BPH
                British Journal of Pharmacology
                John Wiley and Sons Inc. (Hoboken )
                0007-1188
                1476-5381
                26 December 2018
                June 2019
                26 December 2018
                : 176
                : 12 , Themed Section: Immune Targets in Hypertension. Guest Editors: Antony Vinh, Grant R. Drummond and Christopher G. Sobey ( doiID: 10.1111/bph.v176.12 )
                : 1922-1931
                Affiliations
                [ 1 ] Department of Periodontology and Oral Sciences Research Group, University of Glasgow Dental School and Institute of Infection, Immunity and Inflammation University of Glasgow Glasgow UK
                [ 2 ] Department of Dental Prophylaxis and Experimental Dentistry Jagiellonian University School of Medicine Kraków Poland
                [ 3 ] Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK
                [ 4 ] Department of Periodontology Pomeranian Medical University Szczecin Poland
                [ 5 ] Department of Clinical Pharmacology Vanderbilt University Nashville TN USA
                [ 6 ] Department of Internal and Agricultural Medicine Jagiellonian University Medical College Kraków Poland
                Author notes
                [*] [* ] Correspondence Marta Czesnikiewicz‐Guzik, PhD FRCP, Department of Periodontology, Oral Sciences Research Group, Glasgow Dental School, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. E‐mail: marta.czesnikiewicz-guzik@ 123456glasgow.ac.uk
                Author information
                https://orcid.org/0000-0002-7444-1373
                https://orcid.org/0000-0002-5039-7849
                Article
                BPH14536 2018-BJP-0390-RPT-G.R1
                10.1111/bph.14536
                6534780
                30414380
                987995c0-2952-4dbc-8720-2d084bec692d
                © 2018 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 09 April 2018
                : 15 September 2018
                : 09 October 2018
                Page count
                Figures: 5, Tables: 0, Pages: 10, Words: 4926
                Funding
                Funded by: NIH Program project grants
                Award ID: HL‐58000
                Award ID: P01075209
                Funded by: National Institutes of Health (NIH)
                Award ID: HL‐390006
                Award ID: AR‐42527
                Award ID: AI‐44142
                Award ID: EY‐11916
                Award ID: AR‐41974
                Funded by: BHF Centre of Research Excellence, Glasgow
                Award ID: RE/13/5/30177
                Funded by: European Research Council
                Award ID: 726318
                Funded by: Marie Curie Career Integration Grants (CIG)
                Award ID: 631773
                Categories
                Research Paper
                Themed Section: Research Paper
                Custom metadata
                2.0
                bph14536
                June 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.3 mode:remove_FC converted:25.05.2019

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article